EXPECTATIONS
Challenge treatment goals
Rheumatoid Arthritis
for moderate to severe adult TNFi-IR patients
Psoriatic Arthritis
for adult TNFi-IR patients
Ankylosing Spondylitis
for adult TNFi-IR patients
Non-radiographic Axial Spondyloarthritis
with objective signs of inflammation for adult TNFi-IR patients
Limitations of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants, such as azathioprine and cyclosporine, is not recommended.
Atopic Dermatitis
for refractory, moderate to severe patients 12+ years not adequately controlled with other systemic drug products, including biologics
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
Ulcerative Colitis
for moderate to severe adult TNFi-IR patients
Limitations of Use: RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with other potent immunosuppressants such as azathioprine and cyclosporine.
AbbVie Contigo offers patients the resources and
support they need to start and stay on RINVOQ as prescribed.
Questions? Call 1-855-CONTIGO
(1-855-266-8446)
IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor